Literature DB >> 16801442

In vitro and in vivo assessment of linezolid combined with ertapenem: a highly synergistic combination against methicillin-resistant Staphylococcus aureus.

Cedric Jacqueline1, Jocelyne Caillon, Olivier Grossi, Virginie Le Mabecque, Anne-Françoise Miegeville, Denis Bugnon, Eric Batard, Gilles Potel.   

Abstract

Linezolid in combination with ertapenem showed in vitro synergy against methicillin-resistant Staphylococcus aureus strains. We confirmed this interaction in vivo by using a rabbit endocarditis experimental model and simulation of the human pharmacokinetics in animals for both antibiotics. Linezolid plus ertapenem exhibited highly synergistic activity in vivo after 4 days of treatment.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16801442      PMCID： PMC1489782          DOI： 10.1128/AAC.01501-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines.

Authors:  Alan D Tice; Susan J Rehm; Joseph R Dalovisio; John S Bradley; Lawrence P Martinelli; Donald R Graham; R Brooks Gainer; Mark J Kunkel; Robert W Yancey; David N Williams
Journal:  Clin Infect Dis       Date:  2004-05-26       Impact factor: 9.079

2.  In vivo efficacy of linezolid in combination with gentamicin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  Cedric Jacqueline; Nathalie Asseray; Eric Batard; Virginie Le Mabecque; Marie-France Kergueris; Laurent Dube; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Int J Antimicrob Agents       Date:  2004-10       Impact factor: 5.283

3.  In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.

Authors:  Cédric Jacqueline; Dominique Navas; Eric Batard; Anne-Françoise Miegeville; Virginie Le Mabecque; Marie-France Kergueris; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Experimental bacterial endocarditis. II. Survival of a bacteria in endocardial vegetations.

Authors:  D T Durack; P B Beeson
Journal:  Br J Exp Pathol       Date:  1972-02

5.  In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model.

Authors:  Cédric Jacqueline; Eric Batard; Lucia Perez; David Boutoille; Antoine Hamel; Jocelyne Caillon; Marie-France Kergueris; Gilles Potel; Denis Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 6.  Ertapenem: review of a new carbapenem.

Authors:  George G Zhanel; Christel Johanson; John M Embil; Ayman Noreddin; Alfred Gin; Lavern Vercaigne; Daryl J Hoban
Journal:  Expert Rev Anti Infect Ther       Date:  2005-02       Impact factor: 5.091

7.  Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  Fu-Yu Chiang; Michael Climo
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

8.  Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis.

Authors:  Charlene F Dailey; Paul J Pagano; Lewis V Buchanan; Jennifer A Paquette; Joseph V Haas; John K Gibson
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

9.  Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects.

Authors:  D G Musson; A Majumdar; S Holland; K Birk; L Xi; G Mistry; D Sciberras; J Muckow; P Deutsch; J D Rogers
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart.

Authors:  B B Perlman; L R Freedman
Journal:  Yale J Biol Med       Date:  1971-10
View more
  7 in total

1.  Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against Staphylococcus aureus.

Authors:  Sebastian G Wicha; Martin G Kees; Janin Kuss; Charlotte Kloft
Journal:  Pharm Res       Date:  2015-01-30       Impact factor: 4.200

2.  Managing Severe Community-Acquired Pneumonia Due to Community Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Jason C Kwong; Kyra Chua; Patrick G P Charles
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

3.  Methicillin-resistant Staphylococcus aureus endocarditis and de novo development of daptomycin resistance during therapy.

Authors:  L Twele; E Moyen; K Zhang; B Dalton; D Church; J Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

4.  Pharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusion.

Authors:  Maria Saroglou; Stavros Tryfon; Georgios Ismailos; Ioannis Liapakis; Manolis Tzatzarakis; Aristidis Tsatsakis; Apostolos Papalois; Demosthenes Bouros
Journal:  J Inflamm (Lond)       Date:  2010-05-18       Impact factor: 4.981

5.  Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus.

Authors:  A del Río; C García-de-la-Mària; J M Entenza; O Gasch; Y Armero; D Soy; C A Mestres; J M Pericás; C Falces; S Ninot; M Almela; C Cervera; J M Gatell; A Moreno; P Moreillon; F Marco; J M Miró
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

6.  Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus.

Authors:  P Tattevin; L Basuino; D Bauer; B A Diep; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

7.  Pharmacodynamic Functions of Synthetic Derivatives for Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) and Mycobacterium tuberculosis.

Authors:  Mojdeh Dinarvand; Malcolm P Spain; Fatemeh Vafaee
Journal:  Front Microbiol       Date:  2020-11-27       Impact factor: 5.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.